New Studies Support Benefit of Merck's Molnupiravir

Three studies supporting Merck and Ridgeback Biotherapeutics’ Lagevrio (molnupiravir) will be presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022) in Lisbon. The conference runs from April 23-26. Molnupiravir is an oral antiviral authorized in the U.S. and other countries for early treatment of COVID-19.